Cargando…

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial

CONTEXT: For children with growth hormone deficiency (GHD), treatment burden with daily somatropin injections [human growth hormone (hGH)] is high, which may lead to poor adherence and suboptimal overall treatment outcomes. Lonapegsomatropin (TransCon hGH) is an investigational long-acting, once-wee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thornton, Paul S, Maniatis, Aristides K, Aghajanova, Elena, Chertok, Elena, Vlachopapadopoulou, Elpis, Lin, Zhengning, Song, Wenjie, Christoffersen, Eva Dam, Breinholt, Vibeke Miller, Kovalenko, Tatiana, Giorgadze, Elene, Korpal-Szczyrska, Maria, Hofman, Paul L, Karpf, David B, Shu, Aimee D, Beckert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530727/ https://www.ncbi.nlm.nih.gov/pubmed/34272849 http://dx.doi.org/10.1210/clinem/dgab529

Ejemplares similares

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial
por: Saenger, Paul, et al.
Publicado: (2022)

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
por: Maniatis, Aristides K, et al.
Publicado: (2022)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin
por: Hofman, Paul, et al.
Publicado: (2023)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency
por: Lin, Zhengning, et al.
Publicado: (2021)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Iron affects localization of Ght5 in fission yeast
por: Akyüz, Sevim Nur, et al.
Publicado: (2023)

Ultrasound image of the thyroid gland in obese children
por: Szczyrski, Józef, et al.
Publicado: (2015)

InSiGHT leads in the implementation of the Human Variome Project
por: Macrae, Finlay, et al.
Publicado: (2011)

The InSiGHT approach to classification of mismatch repair gene variants
por: Plazzer, JP
Publicado: (2012)

InSiGHT 2022 Abstract Publishing and Best Abstract Awards
Publicado: (2022)

Innovation and entrepreneurship in the HEI sector
por: Ferreira, João
Publicado: (2018)

In Memory of Dr Hei Leung
por: Zeigler, Robert S.
Publicado: (2022)

Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients
por: Miller, Bradley S, et al.
Publicado: (2022)

Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database
por: Peltomäki, Päivi, et al.
Publicado: (2004)

Development and Psychometric Evaluation of an Instrument Assessing Barriers to Growth Hormone Treatment (BAR-GHT)
por: de Zwaan, Martina, et al.
Publicado: (2020)

HEI's mobile air toxics project.
por: Goldstein, B D, et al.
Publicado: (1993)

Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia
por: Makaridze, Zaza, et al.
Publicado: (2014)

The Frequency of Langerhans Islets β-Cells Autoantibodies (Anti-GAD) in Georgian Children and Adolescents with Chronic Autoimmune Thyroiditis
por: Balakhadze, Mariam, et al.
Publicado: (2016)

“Vitamin D Deficiency Is More Common in Women with Autoimmune Thyroiditis: A Retrospective Study”
por: Turashvili, Nino, et al.
Publicado: (2021)

The Role of Rice HEI10 in the Formation of Meiotic Crossovers
por: Wang, Kejian, et al.
Publicado: (2012)

Boosting targeted genome editing using the hei-tag
por: Thumberger, Thomas, et al.
Publicado: (2022)

The Impact of Obesity Assessed by Different Criteria on the Metabolic Parameters in Children and Adolescents in Georgia
por: Tskhvedadze, Nino, et al.
Publicado: (2022)

SUN-272 Persistent Hyperinsulinemic Hypoglycemia Due to Mutation in Hepatocyte Nuclear Factor 4A
por: Vlachopapadopoulou, Elpis, et al.
Publicado: (2019)

Genetic Analysis and Fine Mapping of ZmGHT1 Conferring Glufosinate Herbicide Tolerance in Maize (Zea mays L.)
por: Bao, Jianxi, et al.
Publicado: (2022)

Determinants of the incidence of non-academic staff in European and US HEIs
por: Avenali, Alessandro, et al.
Publicado: (2022)

Analysis of UNESCO ESD Priority Areas’ Implementation in Romanian HEIs
por: Dumitrescu, Corina-Ionela, et al.
Publicado: (2022)

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP
por: Breinholt, Vibeke Miller, et al.
Publicado: (2022)

Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency
por: Janjgava, Shota, et al.
Publicado: (2014)

SAT-055 A De Novo 1p13.2 Deletion Related to Short Stature, Hypothyroidism and Mild Developmental Delay
por: Vlachopapadopoulou, Elpis Athina, et al.
Publicado: (2020)

Editorial: Endocrine and metabolic consequences of childhood obesity
por: Molnár, Dénes, et al.
Publicado: (2022)

Editorial: Endocrine and metabolic consequences of childhood obesity, volume II
por: Mazur, Artur, et al.
Publicado: (2023)

Position statement of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) on APC I1307K and cancer risk
por: Valle, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f9tqle9neo4vpre10q9eao9b3j